A 2021 Update on the Use of Liraglutide in the Modern Treatment of ‘Diabesity’: A Narrative Review
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Obesity and type 2 diabetes mellitus have become a significant public health problem in the past decades. Their prevalence is increasing worldwide each year, greatly impacting the economic and personal aspects, mainly because they frequently coexist, where the term “diabesity” may be used. The drug class of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is one of the most modern therapy options in managing these metabolic disorders. This review focuses on the effects of liraglutide, a long-acting GLP-1 RA, in diabesity and non-diabetic excess weight. This drug class improves glycemic control by enhancing insulin secretion from the beta-pancreatic cells and inhibiting glucagon release. Furthermore, other effects include slowing gastric emptying, increasing postprandial satiety, and reducing the appetite and food consumption by influencing the central nervous system, with weight reduction effects. It also reduces cardiovascular events and has positive effects on blood pressure and lipid profile. A lower-dose liraglutide (1.2 or 1.8 mg/day) is used in patients with diabetes, while the higher dose (3.0 mg/day) is approved as an anti-obesity drug. In this review, we have summarized the role of liraglutide in clinical practice, highlighting its safety and efficacy as a glucose-lowering agent and a weight-reduction drug in patients with and without diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Global aetiology and epidemiology of type 2 diabetes mellitus and its complications
Zheng, Y., Ley, S. H., & Hu, F. B. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.151 · Cited by 5,697
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · cited 1×
“Nevertheless, GLP-1 RAs are not recommended in subjects at high risk of developing MTC, such as a known personal or family history of MTC and/or multiple endocrine neoplasia type 2A and 2B [33,60].”
BackgroundBuse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
Davies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198
(2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.334 · Cited by 1,162
Research works printed but not linked: 26
- Hasanzad, 2020, A narrative review of current trends in liraglutide: Insights into the unmet needs in management of type 2 diabetes and obesity, J. Diabetes Metab. Disord., 19, 1863, 10.1007/s40200-020-00619-9 · DOI
- Feingold, K.R., Anawalt, B., Boyce, A., Chrousos, G., de Herder, W.W., Dhatariya, K., Dungan, K., Grossman, A., Hershman, J.M., and Hofland, J. (2021, March 12). Definitions, Classification, and Epidemiology of Obesity, Endotext [Internet], Available online: https://www.ncbi.nlm.nih.gov/books/NBK279167/.
- International Diabetes Federation (2021, March 12). IDF Diabetes Atlas—9th Edition. DiabetesAtlas. Available online: http://www.diabetesatlas.org/(2019).
- Boles, 2017, Dynamics of diabetes and obesity: Epidemiological perspective, Biochim. Biophys. Acta Mol. Basis Dis., 1863, 1026, 10.1016/j.bbadis.2017.01.016 · DOI · Paper page
- Sims, 1973, Endocrine and metabolic effects of experimental obesity in man, Recent Prog. Horm. Res., 29, 457
- Apovian, 2019, O’Neil PM, Body Weight Considerations in the Management of Type 2 Diabetes, Adv. Ther., 36, 44, 10.1007/s12325-018-0824-8 · DOI · Paper page
- Canuto, 2021, Nutritional intervention strategies for the management of overweight and obesity in primary health care: A systematic review with meta-analysis, Obes. Rev., 22, e13143, 10.1111/obr.13143 · DOI · Paper page
- Seo, 2019, 2018 Korean Society for the Study of Obesity Guideline for the Management of Obesity in Korea, J. Obes. Metab. Syndr., 28, 40, 10.7570/jomes.2019.28.1.40 · DOI · Paper page
- Holst, 2007, The physiology of glucagon-like peptide 1, Physiol. Rev., 87, 1409, 10.1152/physrev.00034.2006 · DOI · Paper page
- Holst, 2013, Incretin hormones and the satiation signal, Int. J. Obes., 37, 1161, 10.1038/ijo.2012.208 · DOI · Paper page
- Velazquez, 2018, Updates on obesity pharmacotherapy, Ann. N. Y. Acad. Sci., 1411, 106, 10.1111/nyas.13542 · DOI
- Vrang, 2001, Glucagon-like peptide containing pathways in the regulation of feeding behaviour, Int. J. Obes. Relat. Metab. Disord., 25, S42, 10.1038/sj.ijo.0801912 · DOI · Paper page
- Vrang, 1998, Glucagon-like peptide1(7-36) amide’s central inhibition of feeding and peripheral inhibition of drinking are abolished by neonatal monosodium glutamate treatment, Diabetes, 47, 530, 10.2337/diabetes.47.4.530 · DOI
- Chilton, 2011, Cardiovascular comorbidities of type 2 diabetes mellitus: Defining the potential of glucagonlike peptide-1-based therapies, Am. J. Med., 124, S35, 10.1016/j.amjmed.2010.11.004 · DOI
- Brown, 2018, Newer GLP-1 receptor agonists and obesity-diabetes, Peptides, 100, 61, 10.1016/j.peptides.2017.12.009 · DOI
- Deacon, 1995, Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type 2-diabetic patients and in healthy subjects, Diabetes, 44, e1131, 10.2337/diab.44.9.1126 · DOI · Paper page
- Abreu, 2019, Profile of semaglutide in the management of type 2 diabetes: Design, development, and place in therapy, Drug Des. Devel. Ther., 13, 731, 10.2147/DDDT.S165372 · DOI
- Brunton, 2020, Integrating oral semaglutide into clinical practice in primary care: For whom, when, and how?, Postgrad. Med., 132, 48, 10.1080/00325481.2020.1798162 · DOI
- Marre, 2009, St on behalf of the LEAD-1 SU study group Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU), Diabet Med., 26, 268, 10.1111/j.1464-5491.2009.02666.x · DOI · Paper page
- Duan, 2019, Cardiovascular outcomes of liraglutide in patients with type 2 diabetes: A systematic review and meta-analysis, Medicine, 98, e17860, 10.1097/MD.0000000000017860 · DOI
- Ueda, 2019, Use of liraglutide and risk of major cardiovascular events: A register-based cohort study in Denmark and Sweden, Lancet Diabetes Endocrinol., 7, 106, 10.1016/S2213-8587(18)30320-6 · DOI
- Davies, 2018, Satiety and Clinical Adiposity–Liraglutide Evidence in individuals with and without diabetes (SCALE) study groups. Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials, Diabetes Obes. Metab., 20, 734, 10.1111/dom.13125 · DOI · Paper page
- Seo, 2021, Side Effects Associated with Liraglutide Treatment for Obesity as Well as Diabetes, J. Obes. Metab. Syndr., 30, 12, 10.7570/jomes20059 · DOI
- Wang, 2018, Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials, Diabetes Obes. Metab., 20, 910, 10.1111/dom.13177 · DOI
- Sfairopoulos, 2018, Clinical pharmacology of glucagon-like peptide-1 receptor agonists, Hormones, 17, 333, 10.1007/s42000-018-0038-0 · DOI
- Tsimihodimos, 2017, Antidiabetic Drugs and the Kidney, Curr. Pharm. Des., 23, 6310, 10.2174/1381612823666170307103222 · doi:10.2174/1381612823666170307103222
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Satiety: a gut–brain–relationship
Barakat, G. M., Ramadan, W., Assi, G., & Khoury, N. B. E. (2024) · The Journal of Physiological Sciences · doi:10.1186/s12576-024-00904-9 · Cited by 82
“Finally, GLP-1 injections into the body over an extended period of time decrease weight gain and promote weight loss [23].”
BackgroundLiraglutide and polycystic ovary syndrome: is it only a matter of body weight?
Pugliese, G., de Alteriis, G., Muscogiuri, G., Barrea, L., Verde, L., Zumbolo, F., Colao, A., & Savastano, S. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02084-6 · Cited by 29
Metadata
- Authors
- Tilinca, M. C., Tiuca, R. A., Burlacu, A., & Varga, A.
- Venue
- Medicina
- Publisher
- MDPI AG
- Published
- 2021-06-29
- Volume
- 57
- Issue
- 7
- Pages
- 669
- ISSN
- 1010-660X (ISSN-L)
- 1648-9144
- OpenAlex
- W3175253874
- Cited by
- 43
- References
- 36
- FWCI
- 1.74
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A 2021 Update on the Use of Liraglutide in the Modern Treatment of ‘Diabesity’: A Narrative Review. https://app.cochat.ai/papers/10.3390/medicina57070669
- The paper
- Tilinca, M. C., Tiuca, R. A., Burlacu, A., & Varga, A. (2021). A 2021 Update on the Use of Liraglutide in the Modern Treatment of ‘Diabesity’: A Narrative Review. Medicina. https://doi.org/10.3390/medicina57070669
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.